Truist cuts Agios Pharma stock price target on SCD concerns
Truist Securities reduced its price target for Agios Pharmaceuticals (NASDAQ: AGIO) to $35 from $37, citing concerns about sickle cell disease. The stock is currently trading at $28.38, down 15.7% over the past week. Agios reported Q3 2026 earnings that missed expectations, but revenue exceeded estimates. The company announced a 35% reduction in R&D headcount, aiming for non-GAAP profitability in 2028.
How this was made
The 30-second read
Why it matters
The price‑target cut signals a shift in analyst sentiment, likely prompting short‑term selling pressure.
Market read
Analyst downgrade with a new target provides a clear, actionable signal for traders.
What to watch
Potential upcoming FDA decision on sickle‑cell program could offset short‑term pressure.
Background
Truist's downgrade follows Agios' Q3 2026 earnings miss and announced R&D headcount reductions.
Ticker impact
Truist Securities lowered its price target on Agios Pharmaceuticals to $35 from $37, citing missed Q3 earnings and cost cuts.
likely pressure as the market prices in the lower target
Target reduction is a fresh analyst downgrade with a concrete new price level, prompting traders to reassess valuation.
Market effects
May affect other rare‑disease biotech stocks as analysts reassess valuation metrics.
Limited to US biotech sector.
Low global impact.
Counterpoint
Some investors may view the target cut as an overreaction given the recent revenue beat.
Key entities
- companyAgios Pharmaceuticals Inc.
Biotech firm developing treatments for rare diseases.
- analystTruist Securities
Research firm providing the price‑target downgrade.
